TrialBMC cancer2025

Baseline tumor burden predicts the efficacy of first-line chemoimmunotherapy in patients with advanced non-small cell lung cancer: results from 2 phase 3 randomized placebo-controlled trials.

Xinyi He et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.